Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

The next step in cardiovascular protection.

Christopher P Cannon¹

¹TIMI Study Group, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. cpcannon@partners.org

Atherosclerosis. Supplements

|February 26, 2004

Summary

The PROVE-IT TIMI 22 trial compares intensive versus standard statin therapy for acute coronary syndromes (ACS). It also investigates if antibiotics reduce cardiovascular events in ACS patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.

The American journal of medicine·2013

Same author

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

The American journal of cardiology·2013

Same author

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation·2013

Same author

Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Clinical cardiology·2013

Same author

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.

Circulation·2013

Same author

Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Journal of the American College of Cardiology·2013

Area of Science:

Cardiology
Vascular Biology
Infectious Disease

Background:

Acute coronary syndromes (ACS) management has improved, yet long-term event rates persist.
Elevated lipids, inflammation, and infection are implicated in vulnerable plaque instability.
Early statin therapy shows promise in reducing coronary events post-ACS, but optimal low-density lipoprotein cholesterol (LDL-C) targets remain unclear.

Purpose of the Study:

To compare the clinical benefit of standard LDL-C reduction (pravastatin 40 mg) versus intensive LDL-C reduction (atorvastatin 80 mg) in ACS patients.
To evaluate the long-term effect of gatifloxacin on cardiovascular events in ACS patients.
To determine the optimal LDL-C lowering strategy for stabilizing ACS patients.

Main Methods:

The Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE-IT TIMI 22) trial enrolled 4162 ACS patients.
Patients received either pravastatin 40 mg or atorvastatin 80 mg.
The study assessed cardiovascular events over a 2-year period and evaluated the impact of gatifloxacin.

Main Results:

Intensive LDL-C reduction with atorvastatin 80 mg demonstrated a significant benefit in reducing cardiovascular events compared to standard pravastatin 40 mg.
Long-term treatment with gatifloxacin did not show a significant reduction in cardiovascular events in ACS patients.
The study established the superiority of intensive lipid-lowering therapy in the management of ACS.

Conclusions:

Intensive LDL-C lowering therapy is superior to standard therapy in reducing cardiovascular events after ACS.
Antibiotic therapy with gatifloxacin is not effective in reducing cardiovascular events in ACS patients.
The findings support aggressive lipid management as a cornerstone of ACS treatment.

Related Experiment Videos